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Abstract
Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a multifunctional secreted
protein with pleiotropic actions, including the inhibition of matrix metalloproteinases (MMPs), cell
death/survival and growth promoting activities. After inflammatory challenge, the levels of TIMP-1
are highly and selectively upregulated in astrocytes among glial cells, but little is know about its role
in these neural cells. We investigated the influence of TIMP-1 null mutation in the reactivity of
cultured astrocytes to pro-inflammatory stimuli with TNF-α and anti-Fas antibody.
Results: When compared to WT, mutant astrocytes displayed an overall increased constitutive
gelatinase expression and were less responsive to Fas-mediated upregulation of MMP-9, of
monocyte chemoattractant protein-1 (MCP-1) and of intercellular cell adhesion molecule-1
(ICAM-1), all markers of astrocyte inflammatory response. In contrast, TNF-α treatment induced
all these factors similarly regardless of the astrocyte genotype. The incorporation of 3H-thymidin,
a marker of cell proliferation, increased in wild-type (WT) astrocytes after treatment with anti-Fas
antibody or recombinant TIMP-1 but not in mutant astrocytes. Finally, lymphocyte chemotaxis was
differentially regulated by TNF-α in WT and TIMP-1 deficient astrocytes.
Conclusion: We provide evidence that the alteration of the MMP/TIMP balance in astrocytes
influences their reactivity to pro-inflammatory stimuli and that Fas activation modulates the
expression of members of the MMP/TIMP axis. We hypothesise that the Fas/FasL transduction
pathway and the MMP/TIMP system interact in astrocytes to modulate their inflammatory response
to environmental stimuli.
Background
Injury in the central nervous system (CNS) is generally
accompanied by an inflammatory reaction that involves
mainly microglia and astrocytes. The latter are the most
abundant cells in the CNS and their contribution to the
pathological outcome is still a matter of debate. In
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Characterisation of astrocyte cultures Figure 1
Characterisation of astrocyte cultures. A. Epifluorescence photomicrographs showing combined labelling with anti-GFAP and 
anti-F4/80 antibodies, and nuclear intercalant Hoechst. Astrocyte culture were charaterised as being greater than 95% pure by 
counting GFAP-positive cells and F4/80-positive cells (microglia) over the total number of cells stained by Hoechst. B. Expres-
sion of TIMP-1 in astrocytes was assessed by western blot; lane 1: mouse recombinant TIMP-1, lane 2: supernatant of WT 
astrocytes and lane 3: supernatant of KO astrocytes. C. Phase contrast photomicrographs of astrocyte cultures. No apparent 
morphological differences were seen between WT and KO astrocytes. D. Effect of treatments on cell viability. Only TNF-α 
treatment induced a mild cytotoxic effect on WT astrocytes. Values represent the mean +/- s.e.m. of at least three independ-
ent experiments. Statistical differences were determined by Student's t-test when comparing treatments to normalised values 
(* p < 0.05). Scale bar represents 50 µm.BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
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Expression of MMP-9 and MMP-2 in astrocytes Figure 2
Expression of MMP-9 and MMP-2 in astrocytes. A. Gelatine zymograms from culture supernatants of WT and KO astrocytes 
in control condition (lane 1) or after treatment with TNF-α (lane 2) and anti-Fas antibody (lane 3). Quantitative expression of 
the 94 kDa (MMP-9) (B) and the 63 kDa form of MMP-2 (C). Constitutive levels of MMP-2 in KO were higher than in WT 
astrocytes. MMP-9 was up-regulated by TNF-α in both strains of astrocytes. Fas activation significantly induced MMP-9 expres-
sion in WT astrocytes but not in KO astrocytes. D. Total gelatinase expression detected in gel zymography. The total gelati-
nase expression was higher in KO astrocytes as compared to WT astrocytes. TNF-α and anti-Fas treatments increased total 
gelatinase expression only in WT astrocytes. Values represent the mean +/- s.e.m. of at least three independent experiments. 
Statistical differences were determined by Student's t-test when comparing treatments to control cells within a given genotype 
(* p < 0.05) or KO vs WT cells (●  p < 0.05).BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
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Expression of ICAM-1 in WT and KO astrocytes Figure 3
Expression of ICAM-1 in WT and KO astrocytes. A. Plots of flow cytometry after treatment with TNF-α or anti-Fas antibody. 
B. Quantification of ICAM-1 expression. ICAM-1 levels were up-regulated by TNF-α in astrocytes from WT and KO mice, 
whereas Fas activation increased ICAM-1 expression only in WT astrocytes. Values represent the mean +/- s.e.m. of at least 
three independent experiments. Statistical differences were determined by Student's t-test when comparing treatments to con-
trol cells (* p < 0.05).BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
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response to injury, cytokines and chemokines trigger
astrocyte proliferation and migration into the lesioned
area where astrocytes contribute to the formation of the
glial scar that inhibits axonal regeneration in the CNS [1].
Characteristic features of reactive astrocytes are morpho-
logical changes with cell body hypertrophy and increased
expression of a number of proteins absent or weakly
expressed in their resting state. Among these proteins, the
MMPs and the TIMPs are highly upregulated in reactive
astrocytes. TIMP-1 is a 31 kDa multifunctional secreted
glycoprotein that possesses, in addition to its MMP inhib-
itor activity, growth promoting activities in a number of
non neural cells [2-4]. We first demonstrated that TIMP-1
is massively and sequentially upregulated in cortical areas
of rat brain after kainate-induced seizures, first in resistant
neurons and subsequently in reactive astrocytes [5]. Selec-
tive TIMP-1 upregulation in astrocytes has also been
reported after experimental autoimmune encephalomy-
elitis [6] or cerebral ischemia [7]. Interestingly, none of
the aforementioned studies reported TIMP-1 expression
in reactive microglial cells, highlighting the possibility of
a specific role for TIMP-1 in astrocytes among glial cells.
In cultured astrocytes, TIMP-1 is induced in response to a
number of pro-inflammatory stimuli, including cytokines
activated in the injured brain such as TNF-α or IL-1 [8-
10], LPS [11] or after transient exposure to activated T
lymphocytes [12]. Nevertheless, the effects of TIMP-1 in
astrocytes are still largely unknown. We thus investigated
the influence of TIMP-1 null mutation [13] on the
response of cultured astrocytes to two cytokines of the
TNF superfamily know to be induced in similar physio-
pathological conditions than TIMP-1. Notably, TNF-α
and the Fas/FasL system are known to be death molecules
for different cell types [14-16], but act as pro-inflamma-
tory agents in astrocytes [17-20] the latter being resistant
to Fas mediated cytotoxic effects [21-23]. In addition, it is
known MMPs may regulate the activity of the TNF and Fas
systems by proteolytic cleavage of some of their members,
including TNF-α [24], TNF-R [25], Fas-L [26,27] and Fas
[28].
We provide evidence that the absence of TIMP-1 prevents
the induction of MMP-9 and of inflammatory markers
such as ICAM-1 or MCP-1 after Fas activation and that the
mutant astrocytes proliferate less than the wild type in
response to cytokines and to TIMP-1. TIMP-1 null muta-
tion is also accompanied by an increased constitutive
expression of gelatinases, mainly MMP-2. Altogether,
these data indicate that the absence of TIMP-1 specifically
attenuates the inflammatory response of astrocytes trig-
gered by Fas but not by TNF-α and suggest that the MMP/

β
Release of MCP-1 by WT and KO astrocytes was measured  in supernatants by ELISA Figure 4
Release of MCP-1 by WT and KO astrocytes was measured 
in supernatants by ELISA. MCP-1 release was up-regulated by 
TNF-α in astrocytes from WT and KO mice, whereas Fas 
activation increased MCP-1 release only in WT astrocytes. 
Values represent the mean +/- s.e.m. of at least three inde-
pendent experiments. Statistical differences were determined 
by Student's t-test when comparing treatments to control 
cells (* p < 0.05).
Astrocyte proliferation was estimated by measuring 3H-thy- midin uptake, expressed in cpm Figure 5
Astrocyte proliferation was estimated by measuring 3H-thy-
midin uptake, expressed in cpm. Note that constitutive 
uptake was higher in KO than in WT astrocytes. Both anti-
Fas antibody and mrTIMP-1 increased proliferation of WT 
astrocytes but not of KO astrocytes. Values represent the 
mean +/- s.e.m. of at least three independent experiments. 
Statistical differences were determined by Student's t test 
when comparing treatments to control cells with the same 
genotype (* p < 0.05) or KO vs WT cells (●  p < 0.05).BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
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TIMP balance is an important determinant in the pro-
inflammatory effects of some members of the TNF family.
Results
Characterisation of astrocyte cultures
Astrocyte cultures were characterised as being greater than
95% pure by counting GFAP positive cells over the total
number of cells stained by Hoechts # 33258. Microglial
cells stained with F4/80 constituted the majority of GFAP
negative cells (Fig. 1A). We confirmed by western blot that
WT astrocytes constitutively expressed TIMP-1 and that
the protein was absent in astrocytes from KO mice (Fig.
1B). As shown in Fig. 1C, no morphological differences
were observed between astrocytes from WT or KO mice
and the density of confluent cells was equivalent. This
observation was supported by the finding that the MTT
levels were identical in untreated WT and TIMP-1 KO cul-
tures. Parallel experiments using propidium iodide as a
cell death marker showed no differences in the constitu-
tive cell death of untreated astrocytes (2–3%) between WT
and mutant mice (results not shown). We found a mild
reduction (16%) in mitochondrial activity by the test MTT
only in WT astrocytes treated by TNF-α and no effect after
anti-Fas antibody exposure (Fig. 1D). We confirmed pre-
vious data [21-23] demonstrating the absence of anti-Fas
toxicity in astrocytes.
TIMP-1 null mutation causes altered expression of MMP-
2 and MMP-9
It is widely accepted that astrocytes express soluble MMP-
2 and 9 (also known as gelatinases A and B, respectively)
and TIMP-1. As TIMP-1 is the preferential inhibitor of
MMP-9 and a good inhibitor of MMP-2, we used gel
zymography to evaluate whether TIMP-1 depletion would
influence the expression of both proteinases in the super-
natants of WT and KO cultures after treatments. In control
cultures, gel zymography (Fig. 2A) revealed the expected
MMP-9 94 kDa band, and a predominant band at 63 kDa
and a weaker band at 68 kDa, both of them coherent with
expected molecular weights for MMP-2 active forms. We
also detected a conspicuous band at 130 kDa. The consti-
tutive levels of MMP-2 were more than twice the levels of
MMP-9 in both WT and mutant astrocytes. TIMP-1 null
mutation had no significant effect on constitutive MMP-9
expression, but increased the baseline levels of MMP-2 by
60%, as compared with WT astrocytes (Fig. 2C). In the lat-
ter, TNF-α and Fas activation significantly increased MMP-
9 expression (80% and 110%, respectively). In the KO
astrocytes, MMP-9 levels were upregulated only after
exposure to TNF-α, while Fas activation had no significant
effect (Fig. 2B). Treatments did not change the levels of
MMP-2 except the anti-Fas antibody which reduced MMP-
2 levels in KO astrocytes. When considering the total pool
of gelatinases detected by gel zymography, we found that
its constitutive level was higher in the KO astrocytes and
increased with TNF-α and anti-Fas antibody in the WT
astrocytes (Fig. 2D). Phenanthroline and BB-3103 abol-
ished gelatinase activity, indicating that it was generated
by metalloproteinases (not shown).
ICAM-1 and MCP-1 are differentially induced in WT and 
TIMP-1 KO astrocytes
Astrocytes are the most abundant cells of the brain and
express cytokines and adhesion molecules involved in dif-
ferent phases of neuroinflammation, including leukocyte
recruitment in the CNS. Among these proteins, ICAM-1
and MCP-1 are strongly up-regulated during neuroinflam-
mation, and preferentially in astrocytes [29-32]. Accord-
ingly, both proteins are considered as markers of
inflammatory response. In addition, the activities of
ICAM-1 and MCP-1 are modulated by metalloproteinases
[33,34]. For these reasons we examined whether the
imbalance in the MMP/TIMP ratio observed in the mutant
cultures would affect the levels of ICAM-1 and MCP-1 in
astrocytes. As illustrated in figures 3 and 4, we found no
differences in the constitutive expression of membrane
bound ICAM-1 or release of MCP-1 between WT and KO
cultures. However, exposure to TNF-α increased ICAM-1
levels in both WT and KO cultures (120% and 80%,
respectively) (Fig. 3). An even higher upregulation of
MCP-1 levels was observed after TNF-α in WT (215%) and
KO (310%) (Fig. 4). In contrast, Fas activation upregu-
lated ICAM-1 (70%) and MCP-1 (150%) levels only in
WT mice, but not in TIMP-1 deficient astrocytes.
KO astrocytes proliferate less than WT astrocytes in 
response to TNF-α and anti-Fas
Since cell proliferation is a hallmark of glial response to
neuroinflammatory challenge, we measured the incorpo-
ration of 3H-thymidin, as an index of proliferation, into
first passage synchronised astrocytes in response to
cytokines and mrTIMP-1 (Fig. 5). We show that mrTIMP-
1 induced the highest increase (200%) in proliferation of
WT cells. Even though the levels of 3H-thymidin uptake in
KO astrocytes treated with TIMP-1 were equivalent to
those of WT astrocytes, statistical significance with respect
to the untreated KO control was not reached, possibly
because of a high level of constitutive 3H-thymidin incor-
poration in the mutant astrocytes. TNF-α did not signifi-
cantly stimulate 3H-thymidin uptake in WT and KO
astrocytes, unlike anti-Fas antibody that induced a signif-
icant 40% increase in WT but not in KO astrocytes.
Effect of WT and KO astrocytes on lymphocyte 
recruitment
MCP-1 is one of the main chemokines involved in the
chemoattraction of monocytes and lymphocytes under
inflammatory conditions [35,36]. We investigated
whether WT astrocytes showing a dramatic upregulation
of MCP-1 after exposure to TNF-α or anti-Fas antibody,BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
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would differentially affect lymphocyte migration as com-
pared with KO astrocytes whose levels of MCP-1 were
unaltered by anti-Fas antibody treatment. The data (Fig.
6) show that astrocytes alone increased by 300% the
number of migrating lymphocytes regardless of the geno-
type. Moreover, in the absence of astrocytes, anti-Fas anti-
body alone was sufficient to significantly increase (200%)
lymphocyte migration. However, the incubation of astro-
cytes with TNF-α increased the chemotaxis of lym-
phocytes, in particular in the KO astrocytes. In contrast,
no effect of anti-Fas antibody was observed in WT or KO
astrocytes as compared to their controls.
Discussion
The present report shows that TIMP-1 null mutation
attenuates the inflammatory response of astrocytes to Fas
activation. We show that TIMP-1 null mutation is associ-
ated with a higher constitutive MMP-2 expression, and
that Fas activation fails to induce MMP-9, ICAM-1 and
MCP-1 expression in KO astrocytes as it is the case in WT
astrocytes. Moreover, KO astrocytes proliferate less than
WT in response to anti-Fas and mrTIMP-1, whereas
recruitment of lymphocytes is significantly induced only
by TNF-α-treated astrocytes from KO mice.
The constitutive expression of gelatinases in general, and
MMP-2 in particular, is higher in KO than in WT astro-
cytes, suggesting that in the absence of TIMP-1, the base-
line regulation of one of its main targets is altered. The
overall increase in gelatinase expression along with the
absence of TIMP-1-mediated inhibition of MMPs in
mutant astrocytes presumably increases MMP activity. As
demonstrated previously in other cell types [37] and in
brains from TIMP-1 KO mice [38], we assume that TIMP-
1 deficiency is not compensated by the overexpression of
other TIMPs, at least at the mRNA level. Our data showing
a weak decrease of the mitochondrial activity after TNF-α
exposure could be interpreted as a mild cytotoxic effect in
agreement with studies reporting <20% astrocyte cell
death after exposure to the cytokine [39]. We can not rule
out the possibility that the absence of cell death under
TNF treatment in KO astrocytes may be actually related to
a relatively higher baseline proliferative potential in these
cultures. We also show that astrocytes are resistant to Fas-
mediated cell death in keeping with previous findings in
human [21,22] and mouse astrocyte cultures [23]. More-
over, the TNF-α mediated induction of MMP-9 found in
mouse astrocytes was equivalent to that reported in rat
astrocytes [40]. However, this is the first report demon-
strating that the activation of Fas stimulates MMP-9
release by astrocytes. Together, these data support the idea
that the activation of receptors of the TNF superfamily
triggers inflammatory rather than death signals in astro-
cytes, and that MMP-9 could act as an inflammatory factor
downstream of Fas activation. It is likely that the induced
expression of MMP-9 amplifies the inflammatory cascade
initiated by cytokines through mechanisms involving the
proteolytic activation of latent forms of cytokines. MMP-
9 can proteolytically convert latent forms of TNF-α and IL-
1β into active forms [24,41]. The presumably pro-inflam-
matory role of MMP-9 in astrocytes does not preclude its
cytotoxic action demonstrated for cortical [42] and hip-
pocampal [43] neurons in excitotoxic/inflammatory para-
digms.
The most striking finding of the present study was the
reduced response displayed by TIMP-1 deficient astrocytes
to anti-Fas antibody, in clear contrast with the response of
The effect of astrocytes on lymphocyte migration was  assessed using Transwell chambers and was expressed by the  total number of migrated cells (A) and as an index of migra- tion (B) Figure 6
The effect of astrocytes on lymphocyte migration was 
assessed using Transwell chambers and was expressed by the 
total number of migrated cells (A) and as an index of migra-
tion (B). Note that anti-Fas treatment alone without astro-
cytes in the lower compartment induced lymphocyte 
migration. Only KO astrocytes treated with TNF-α induced 
significant lymphocyte migration. Values represent the mean 
+/- s.e.m. of at least three independent experiments. Statisti-
cal differences were determined by Student's t-test when 
comparing treatments to control cells (* p < 0.05) or astro-
cytes vs no astrocyte (●  p < 0.05).BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
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their WT counterparts. Failure in inducing MMP-9, ICAM-
1 and MCP-1 strongly suggests that the absence of TIMP-
1 disturbs the Fas signal transduction pathway. TIMPs are
considered as multifunctional proteins with anti-MMP,
cell-death/survival, and growth promoting activities [44].
Some of the mechanisms underlying these actions are
related with the ability of TIMPs to prevent proteolytic
processing of membrane receptors, such as death recep-
tors of the TNF superfamily. It has been suggested that the
stabilisation of Fas by endogenous (TIMP-1 and TIMP-3)
and synthetic MMP inhibitors is responsible for increased
sensitivity to apoptosis of various cell types, including
Dev neural precursors cells [45] or cancer cells [46].
Recently, MMP-7 has been identified as a sheddase of Fas
that induces apoptosis resistance in tumour cells [47].
Considering that astrocytes express high constitutive lev-
els of Fas [23] and that astrocytes deficient for TIMP-1
likely have an increased proteolytic activity, we hypothe-
sise that constitutive cleavage of Fas may indeed reduce
the levels of Fas at the membrane, and consequently ham-
per astrocyte reactivity to anti-Fas antibody treatment.
MMP-2, whose levels are constitutively increased in TIMP-
1 KO astrocytes, decreased however after anti-Fas treat-
ment. It is tempting to speculate that elevated levels of
MMP-2 contribute directly or indirectly to Fas cleavage in
normal conditions. The exposure of cells to a Fas-L-like
factor would favour the downregulation of MMP-2 in an
attempt to re-establish the levels of the receptor. Neverthe-
less, the role of MMP-2 as a Fas sheddase has not been
demonstrated yet.
Together, these data bring support to the hypothesis that
TIMP-1 exerts a pro-inflammatory effect by facilitating
astrocyte reactivity through the regulation of the MMP/
TIMP balance. Astrocyte proliferation is a hallmark of
reactivity in inflammatory settings. For the first time, we
demonstrate that TIMP-1 induces astrocyte proliferation
and this effect is stronger than the effects mediated by
TNF-α or anti-Fas antibody. Our data support the idea
that TIMP-1 exerts a control on cell growth, as previously
suggested by other authors in different cell types [48,4].
Moreover, it has been shown that TIMP-1 accumulates in
the nucleus of some cell types [49] and it has been sug-
gested that it could regulate the cell cycle via a MMP-inde-
pendent mechanism. This idea is reinforced by the finding
in our laboratory that mrTIMP-1 increases by 2-fold the
number of astrocytes in a mixed neuronal-astrocyte cul-
ture, and that this effect is not mimicked by broad spec-
trum MMP inhibitors (unpublished results). The baseline
level of 3H-thymidin uptake in KO astrocytes was higher
than in the WT. Perhaps, for this reason, a pro-inflamma-
tory stimulus with cytokines or TIMP-1 did not induce fur-
ther significant increases in KO astrocyte proliferation. It
is possible that a low constitutive expression of TIMP-1
maintains astrocytes in a resting "low proliferative" state
that reacts promptly to a pro-inflammatory stimulus. On
the contrary, the chronic absence of TIMP-1 may cause a
state of permanent mild "reactivity" or "inflammatory sta-
tus" that increases the response threshold for new exoge-
nous pro-inflammatory stimuli. From the above, it
follows that TIMP-1 might actually act as a homeostatic
factor for astrocytes in the resting state, and as a pro-
inflammatory factor in stressful conditions, notably in
seizing and ischemic brains, where early and massive
induction of TIMP-1 in neurons [5,7] precede astrocyte
reactivity. Pro-inflammatory effects of TIMP-1 have also
been suggested in in vivo models of rheumatoid arthritis
[50].
We expected that mutant astrocytes resistant to Fas-medi-
ated induction of MCP-1 would attract lymphocytes less
efficiently than WT astrocytes displaying a strong upregu-
lation of MCP-1 in the same treatment conditions. The
fact that untreated astrocytes did increase by 300% the
number of migrating lymphocytes clearly indicates that
these glial cells have a strong chemoattractant capacity in
culture conditions, perhaps in part because of their consti-
tutive MCP-1 release. Moreover, the finding that anti-Fas
antibody alone caused a 200% increase in lymphocyte
migration reveals also a potent chemotactic effect of FasL,
independently of its cellular source, in clear contrast with
the absence of chemotactic effects of TNF-α alone. These
data are coherent with previous reports demonstrating
that soluble FasL is chemotactic for neutrophils and that
an anti-Fas antibody mimics this effect [51]. In addition,
it has been shown that Fas activation stimulates motility
in the absence of cytotoxicity [52]. In our experimental
model, it its possible that the threshold of stimulation
necessary for Fas/astrocyte-mediated lymphocyte migra-
tion is already achieved by the individual components of
the tandem.
The strong chemoattractant effect of TIMP-1 deficient
astrocytes when exposed to TNF-α, cannot be interpreted
on the basis of the MCP-1 release, since the latter was
equivalent in both WT and TIMP-1 deficient cells. This
finding suggests that MCP-1 alone is not sufficient to crit-
ically influence the chemoattraction of lymphocytes. The
activity of MCPs is regulated by MMP-mediated proteo-
lytic processing, resulting in new bioactive truncated pro-
teins with antagonist effects on leukocyte migration. In
this scenario, MMPs would indirectly act as anti-inflam-
matory agents [34]. However, we cannot speculate on a
possible interaction between gelatinases (MMP-2 and
MMP-9) and MCP-1 since the latter has been reported to
be specifically cleaved by MMP-1 and MMP-3 [34]. An
alternative way of interpreting the increased lymphocyte
migration in the TIMP-1 deficient astrocytes exposed to
TNF-α, refers to the possible regulation of ICAM-1 by gela-
tinases at the surface of astrocytes; MMPs cleave mem-BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
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brane-bound ICAM-1 in astrocytes [53], and MMP-9
appears to be the key enzyme processing ICAM-1 in
tumour cells [54]. Soluble ICAM-1 (sICAM-1) generated
by this cleavage has been reported to induce macrophage
inflammatory protein-2 (MIP-2) in mouse astrocytes and
subsequently stimulate leucocytes migration [55]. A lower
TIMP-1 inhibitory capacity in the mutant astrocytes, along
with an increased gelatinase activity, would favour
sICAM-1 proteolytic generation and possibly lymphocyte
migration after TNF-α treatment. This idea is coherent
with the overall lower ICAM-1 levels found in the TIMP-1
KO mice.
Conclusion
In summary, the present data provide evidence linking the
MMP/TIMP balance to the reactive response of astrocytes
following pro-inflammatory stimuli. The control of astro-
cyte reactivity by the MMP/TIMP axis affects in a particular
way the Fas/FasL pathway, and suggests that in astrocytes,
the outcome of the neuroinflammatory status in patho-
logical situations may involve the mutual regulation of
these two molecular systems. We can not exclude that
other MMP substrates (ICAM, MCPs) are also affected by
changes in the proteolytic balance. We are just starting to
unveil the importance that the proteolytic modification of
bioactive factors may have in the control of cell behaviour
and intercellular communication. The study of the MMP/
TIMP roles in neural cells and of the mechanisms whereby
these proteinases and inhibitors exert the control of cell
behaviour is a challenging question that needs further
investigation.
Methods
Animals
All experimental procedures were performed in compli-
ance with our institutional guidelines after obtaining the
authorisation of the Laboratory Animal Committee of the
Medical Faculty.
TIMP-1 deficient mice (Sv-129) were generated by homol-
ogous recombination and functional TIMP-1 protein was
detected in WT cells, but not in co-isogenic cell lines car-
rying the mutation in Timp1 [13]. Genetically modified
(KO) and WT mice have an identical genetic background.
Genomic DNA was extracted from the tail tips of mice to
determine their genotype by PCR.
Astrocyte cultures
Astrocytes were obtained from the brains of 2-day-old
mice. After removal of the meninges, the brains were dis-
sociated into a single-cell suspension by trypsinisation
and mechanical disruption. The cells were seeded on
poly-L-lysine (Sigma St Louis, MO, USA) coated culture
plates at the density of 4 × 104 cells per cm2 and grown at
37°C in a 5% CO2 humidified atmosphere in Dulbecco's
Modified Eagle Medium (DMEM) containing 10% foetal
calf serum, 2 mM L-glutamine, penicillin (100 U/ml) and
streptomycin (100 µg/ml) (all from InVitrogen, Carlsbad,
CA, USA). The medium was replaced every 3 days. After
8–10 days in vitro, the medium was changed for 24 h into
serum free medium containing DMEM, 2 mM L-
glutamine, penicillin (100 U/ml), streptomycin (100 µg/
ml), 5 µg/ml insulin (Sigma,) and 0,05% bovine serum
albumin (BSA – InVitrogen). Cells were then treated for
24 h with 10 ng/ml TNF-α (R&D Systems, Minneapolis,
MN, USA) and 0.5 µg/ml hamster anti-mouse Fas anti-
body (Clone Jo2, BD Pharmingen, San Jose, CA, USA)
which mimics the effects of FasL, activates Fas and stimu-
lates pro-inflammatory responses from astrocytes [23].
Western blot
Protein concentration of culture supernatants was nor-
malised using the Lowry method (DC-Protein assay, Bio-
Rad, Hercules, CA, USA). Using a Bio-Rad MiniBlot sys-
tem, equal amounts of protein were subjected to 8.5%
sodium dodecyl sulphate – polyacrylamide gels electro-
phoresis (SDS-PAGE), under reducing and denaturing
conditions, and then transferred to PVDF immunoblot-
ting membrane (Amersham Pharmacia Biotech, Bucking-
hamshire, UK). TIMP-1 was detected by a goat anti-mouse
TIMP-1 antibody (R&D Systems), followed by bioti-
nylated anti-goat IgG and streptavidin-peroxidase (both
from Jackson ImmunoResearch, West Grove, PA, USA),
and then visualised by chemiluminescence reaction using
the ECL system (Amersham). Glycosylated mouse recom-
binant (mr) TIMP-1 (R&D Systems) was used as a control
in each gel.
Astrocyte and microglia staining
In order to charaterise the cell type composition of our
cultures we used glial fibrillary acidic protein (GFAP) as
an astrocytic marker and F4/80 as a microglial marker.
Briefly, cells were preincubated with 0.1% triton X-100
and 5% normal goat serum (NGS) for 30 min, incubated
with rabbit anti-cow GFAP (DAKO, Glostrup, Denmark)
(1/500) and rat anti-mouse F4/80 (Serotec, Kidlington,
Oxford, UK) (1/500) antibodies diluted in PBS contain-
ing 0.1% triton X-100 and 5% serum for 1 h. Cells were
then rinsed in PBS, incubated for 1 h with Alexa Fluor®
594 anti-rabbit and Alexa Fluor® 488 anti-rat antibodies
respectively (Molecular Probes, Eugene, OR, USA), rinsed
in PBS, and the DNA intercalant Hoechts #33258 (Molec-
ular Probes) was added during 5 min to label cell nuclei.
Cells were then mounted in fluorescent mounting
medium (DAKO), observed under a Nikon E800 upright
microscope (Nikon Champigny-sur-Marne, France)
equipped with epifluorescence, TRITC, FITC and DAPI fil-
ters, DXM 1200 camera and the LUCIA image analysis
software.BMC Neuroscience 2005, 6:68 http://www.biomedcentral.com/1471-2202/6/68
Page 10 of 12
(page number not for citation purposes)
3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay
In order to test a possible cytotoxic effect of treatments,
TNF-α and anti-Fas antibody were incubated for 24 h and
cell death measured by the MTT (Sigma) assay that detects
mitochondrial activity in living cells [56]. Results are
expressed as the arbitrary units of optical density. The
means ± S.E.M. were obtained from triplicates within a
single experiment and at least three independent experi-
ments.
Gel zymography
Equal amounts of protein were subjected to 8.5% SDS-
PAGE containing 0.5% gelatine (Sigma) in non-denatur-
ing, non-reducing conditions. Gels were washed twice for
15 min in 2.5% Triton X-100 to remove SDS, and incu-
bated at 37°C for 22 h in 100 mM Tris pH 7.4 and 15 mM
CaCl2. Gels were then stained with 0.1% Coomassie blue
R-250 (Bio-Rad) for 20 min and distained in 10% acetic
acid until clear bands of gelatinolysis appeared on a dark
background. Bacterial collagenase (10-2 U/ml, Sigma) was
loaded in each gel as a control and used for normalisa-
tion. Gels were scanned and bands were quantified using
GeneTools software. Each test was performed in triplicate
within single experiments and means ± S.E.M. were
obtained from at least three independent experiments.
Some zymogram gels were incubated with 1 mM 1,10-0-
phenanthroline (Sigma) or BB-3103, two broad spectrum
inhibitors of metalloproteinases.
Flow cytometry
Astrocyte cultures were incubated on ice for 15 min with
the rat anti-mouse ICAM-1 antibody purified from the
supernatants of YN1 hybridoma cells (R&D Systems).
After washes, cells were treated with FITC-labelled goat
anti-rat IgG (Jackson ImmunoResearch) for 15 min in ice.
Cells were washed, centrifuged and resuspended in PBS
and 2% paraformaldehyde. A control without anti-ICAM-
1 antibody served as blank to normalise the mean of flu-
orescence. FACS analysis was performed on a FACScalibur
(Becton Dickinson, Franklin Lakes, NJ, USA) using Cel-
lquest Software (Becton Dickinson). The number of posi-
tive cells in each assay was standardised to 5000. Results
were expressed in arbitrary units corresponding to the
mean of fluorescence, and were obtained from at least
three independent experiments.
Enzyme linked immuno-adsorbent assay for MCP-1
MCP-1 expression in astrocyte supernatants was measured
using an ELISA kit (BD Pharmingen) according to the
manufacturer's instructions. Equal amounts of protein
were added onto anti-mouse MCP-1 antibody-coated
wells, detected by horseradish peroxydase-conjugated
anti-mouse MCP-1 antibody and revealed with o-phe-
nylenediamine. Recombinant mouse MCP-1 was used as
control to determine the concentration of MCP-1 in the
sample. Each test was performed in triplicate within single
experiments and means ± S.E.M. were obtained from at
least three independent experiments.
Proliferation assay by 3H-thymidin incorporation
After 8–10 days in vitro, astrocytes were trypsinised and
reseeded in serum containing medium in 96-well flat-bot-
tom plates, at the density of 104 cells per well. Twenty four
hours after, the culture medium was replaced with serum-
free medium for 24 h and cells were then treated with
TNF-α, anti-Fas antibody or mrTIMP-1 in triplicate. Two
days later, 1 µCi of 3H thymidin (Amersham Pharmacia
Biotech) was added in each well. After 18 h, cells were har-
vested on filter mats, dried and counted using 1600TR liq-
uid scintillation analyser (Pachard Instruments, Meriden,
CT, USA). The results were expressed as total cpm. Each
test was performed in triplicate within single experiments
and means ± S.E.M. were obtained from at least three
independent experiments.
Lymphocyte recruitment in transwell chambers
We used a transwell system in order to evaluate the influ-
ence of astrocytes treated with TNF-α and anti-Fas anti-
body on lymphocyte migration. Lymphocytes were
obtained from spleen, cultured at 4 × 104 cells per cm2 and
activated with recombinant IL-2 (InVitrogen) and with
the supernatant of splenic cells stimulated with concana-
valin A (Sigma). Astrocytes were seeded in the lower part
of the well, as described above, and treated for 24 h with
TNF-α or anti-Fas antibody in a serum free medium. Lym-
phocytes were labelled with 10 µM CFSE (5-(and-6)-car-
boxyfluorescein diacetate, succinimidyl ester (5(6)-CFDA,
SE; CFSE – Molecular Probes) by a 15 min incubation.
Lymphocytes (1.5 × 104 per well) were then seeded on the
upper part of 3 µm pore clear polycarbonate transwells
(Costar, Cambridge, MA, USA) and allowed to migrate for
7 hours. The filters were then removed and photomicro-
graphs of migrated lymphocytes in the lower well were
taken using a Nikon TE300 inverted microscope equipped
a FITC filter, and images were analysed using a DXM 1200
camera and the LUCIA image analysis software (Nikon).
Wells without astrocytes in the lower part or astrocytes
without treatment were used as controls. The number of
labelled lymphocytes in the lower compartment was
quantified using GenTools software (Syngene). Tests were
performed in triplicate within single experiments and
means ± S.E.M. were obtained from three independent
experiments.
List of abbreviations
CNS, central nervous system; ICAM-1, intercellular adhe-
sion molecule-1; MCP-1, monocyte chemoattractant pro-
tein-1; MMP, matrix metalloproteinase; TIMP, tissue
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